We developed a partitioned survival model to reflect the disease progression and treatment pattern of NSCLC with three health states, referring to progression-free survival, post-progression survival, and death. The proportion of patients in each state was estimated based upon parametric survival equations. Clinical efficacy data was extracted from trial ARCHER1050. Costs and utilities for each line of treatments were generated from publications. A discount of 3% per year was applied. Qualityadjusted life-years (QALYs) were used as the primary health outcome. The health outcome of QALY and the incremental cost effectiveness ratio (ICER) were calculated. One-way sensitivity and probabilistic sensitivity analyses were conducted to test the uncertainty of the model. Results: In the base-case scenario, dacomitinib resulted in a gain of 0.
EML) of 2017 was analyzed. List of medicines registered in Armenia (2018) was analyzed to identify authorized tracer medicines. Data on availability and prices were collected from pricelists of 5 main wholesalers, 3 pharmacy chains and 10 independent pharmacies. Affordability was calculated using methodology developed by WHO and Health Action International; it was expressed as the number of days needed by a person who earns the minimum wage that was set by legislation, to purchase a course of treatment. RESULTS: Only 72.5% of 51 antineoplastics and immunosuppressives and 65.0% of 103 formulations of these medicines listed in WHO EML are included in the new Armenian EML (72.3% and 54.3%, correspondingly, in Armenian EML of 2013); 68.6% of tracer medicines and 44.7% of their formulations are authorized. 49.0% of medicines and 25.2% of formulations were found in wholesalers' pricelists. Only 19.4% of formulations were available in different pharmacy outlets; the most of chain and all independent pharmacies did not have any tracer medicine. Only 16 of 86 formulations of cytotoxic and adjuvant medicines listed in WHO EML were available on the market; and cost of treatment only for 3 of them was less than 1 day wage. CONCLUSIONS: Only less than half of essential antineoplastics and immunosuppressives and less than one quarter of their formulations recommended by WHO are available on the pharmaceutical market of Armenia. Cost of treatment for the great majority of these essential medicines is unaffordable for those patients who are not covered by the reimbursement system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.